State · Midwest

GLP-1 telehealth in Indiana

Indiana's obesity rate of roughly 37% is meaningfully above the national average. Eli Lilly's headquarters in Indianapolis gives the state an outsized presence in clinical research on GLP-1 and dual-agonist therapies. Indianapolis, Fort Wayne, and Evansville have the strongest clinician availability.

Top providers serving Indiana

NexLife
Flat-rate compounded GLP-1 with full pharmacy disclosure
96
/100
Ro Body
Established brand, dual compounded + brand-name routes
86
/100
Henry Meds
Low entry price, watch the mid-dose upcharges
80
/100

Telehealth practice in Indiana

Standard telehealth practice; Indiana Medical Licensing Board licensure required.

Regulatory context

Eli Lilly's headquarters and manufacturing in Indianapolis produce a slightly higher density of obesity-medicine clinical research presence in the state.

Metros covered in Indiana

Indianapolis